A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 146 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Tepotinib December 23, 2021 Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated... April 1, 2025 Caregivers Empower the Next Generation of Cancer Care August 3, 2023 Combination of Azacitidine and Venetoclax in Previously Untreated AML August 18, 2020 Load more HOT NEWS Cancer Survivor with Strong Family History Was Denied Regular Screening Because... Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... One in Five of Older Patients with EBC Treated in a...
